These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27802290)

  • 81. Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson's Disease.
    Chen NC; Chen HL; Li SH; Chang YH; Chen MH; Tsai NW; Yu CC; Yang SY; Lu CH; Lin WC
    Front Aging Neurosci; 2020; 12():112. PubMed ID: 32410983
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging.
    Dugger BN; Serrano GE; Sue LI; Walker DG; Adler CH; Shill HA; Sabbagh MN; Caviness JN; Hidalgo J; Saxon-Labelle M; Chiarolanza G; Mariner M; Henry-Watson J; Beach TG;
    J Parkinsons Dis; 2012 Jan; 2(1):57-65. PubMed ID: 22924088
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Comparing Cerebral White Matter Lesion Burdens between Parkinson's Disease with and without Dementia.
    Choi SA; Evidente VG; Caviness JN
    J Mov Disord; 2010 May; 3(1):6-10. PubMed ID: 24868371
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Post-cueing deficits with maintained cueing benefits in patients with Parkinson's disease dementia.
    Gräber S; Liepelt-Scarfone I; Csoti I; Maetzler W; Sultan F; Berg D
    Front Neurol; 2014; 5():236. PubMed ID: 25477860
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Is Dementia in Parkinson' Disease Related to Chronic Stress, Anxiety, and Depression?
    Pal A; Pegwal N; Behari M; Sharma R
    Ann Indian Acad Neurol; 2019; 22(4):409-413. PubMed ID: 31736560
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Novel evidence associates higher plasma α-synuclein levels and cognitive impairment in Parkinson's disease.
    Aarsland D; Rajkumar AP; Hye A
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):808. PubMed ID: 28607120
    [No Abstract]   [Full Text] [Related]  

  • 87. Antioxidant and Neuroprotective Effects of Caffeine against Alzheimer's and Parkinson's Disease: Insight into the Role of Nrf-2 and A2AR Signaling.
    Ikram M; Park TJ; Ali T; Kim MO
    Antioxidants (Basel); 2020 Sep; 9(9):. PubMed ID: 32971922
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Parkinson's disease and autoimmunity.
    Møller A; Perrild H; Pedersen H; Høier-Madsen M
    Acta Neurol Scand; 1989 Feb; 79(2):173-5. PubMed ID: 2711825
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Purification of Natural Antibodies Against Tau Protein by Affinity Chromatography.
    Krestova M; Hromadkova L; Ricny J
    Methods Mol Biol; 2017; 1643():33-44. PubMed ID: 28667528
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Injury.
    Fiandaca MS; Gross TJ; Johnson TM; Hu MT; Evetts S; Wade-Martins R; Merchant-Borna K; Bazarian J; Cheema AK; Mapstone M; Federoff HJ
    Metabolites; 2018 Sep; 8(3):. PubMed ID: 30205491
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Immunoadsorption of Agonistic Autoantibodies Against α1-Adrenergic Receptors in Patients With Mild to Moderate Dementia.
    Hempel P; Heinig B; Jerosch C; Decius I; Karczewski P; Kassner U; Kunze R; Steinhagen-Thiessen E; Bimmler M
    Ther Apher Dial; 2016 Oct; 20(5):523-529. PubMed ID: 27096216
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Current Status and Prospective Regarding the Therapeutic Potential of Natural Autoantibodies in Cancer Therapy.
    Ebrahimnezhad S; Jazayeri M; Hassanian SM; Avan A
    J Cell Physiol; 2017 Oct; 232(10):2649-2652. PubMed ID: 28063224
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Autoimmune mechanisms in Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1989 Oct; 48(3-4):369-75. PubMed ID: 2583953
    [No Abstract]   [Full Text] [Related]  

  • 94. What Would Dr. James Parkinson Think Today? Tau and Other Imaging Possibilities in Parkinson's Disease.
    Vaillancourt DE
    Mov Disord; 2017 Jun; 32(6):805-806. PubMed ID: 28597559
    [No Abstract]   [Full Text] [Related]  

  • 95. AstraZeneca nabs genomics giants.
    Nat Biotechnol; 2016 Jun; 34(6):583. PubMed ID: 27281404
    [No Abstract]   [Full Text] [Related]  

  • 96. Role of Specific Autoantibodies in Neurodegenerative Diseases: Pathogenic Antibodies or Promising Biomarkers for Diagnosis.
    Miteva D; Vasilev GV; Velikova T
    Antibodies (Basel); 2023 Dec; 12(4):. PubMed ID: 38131803
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Microbial amyloids in neurodegenerative amyloid diseases.
    Sampson T
    FEBS J; 2023 Dec; ():. PubMed ID: 38041542
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Alpha-Synuclein in Peripheral Tissues as a Possible Marker for Neurological Diseases and Other Medical Conditions.
    Jiménez-Jiménez FJ; Alonso-Navarro H; García-Martín E; Santos-García D; Martínez-Valbuena I; Agúndez JAG
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627328
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Natural IgG antibodies to β amyloid are decreased in patients with Parkinson's disease.
    Paganelli R; Paganelli A; Pawelec G; Di Iorio A
    Immun Ageing; 2023 Mar; 20(1):13. PubMed ID: 36906630
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases.
    Kocurova G; Ricny J; Ovsepian SV
    Theranostics; 2022; 12(7):3045-3056. PubMed ID: 35547759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.